Lin and A
This study is the fifth in a line of randomised trials its STEP 5, with the first four STEPs being published in 2021 with impressive results
But GLP-1-receptor agonists such as liraglutide reduce cerebrospinal fluid secretion and have already proved effective in treating idiopathic intracranial hypertension (IIH)
Some wins Im incredibly proud of: -Generated 127M+ total impressions on TikTok - We started from 73M 84M 127M impressions once Brand Awareness was activated - Engagement increase: 13.3M 16.9M 22.3M The best part
Semaglutide is the most extensively studied GLP-1RA, with multiple trials, including SUSTAIN-6, PIONEER-6, FLOW, and SOUL [20,21,22, 31], collectively establishing a robust evidence base for cardiorenal risk reduction in T2D, with SELECT extending these benefits to adults with overweight/obesity and established ASCVD without diabetes [32]
For those considering tirzepatide or currently using it, having access to reliable medical advice is essential